Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Patrick Christian Hermann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0418-0478; OpenAlex author ID A5056191434. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
92
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 23

  1. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-026-48584-2↗
  2. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  3. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. Co-author DOI 10.1186/s12951-024-03010-5↗
  4. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  5. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  6. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  7. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Last author DOI 10.3390/cancers13133145↗
  8. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Co-author DOI 10.1038/s41467-020-16395-2↗
  9. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Co-author DOI 10.1038/s41467-020-18954-z↗
  10. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Last author DOI 10.1101/2020.11.02.361931↗
  11. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  12. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  13. The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures. Co-author DOI 10.1155/2019/1378639↗
  14. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Last author DOI 10.1155/2019/8475389↗
  15. EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells. Last author DOI 10.3390/cancers11081136↗
  16. Pancreatic cancer stem cells: A state or an entity? Co-author DOI 10.1016/j.semcancer.2018.08.007↗
  17. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . Co-author DOI 10.5414/cn109327↗
  18. The ever-changing landscape of pancreatic cancer stem cells. Co-author DOI 10.1016/j.pan.2016.04.004↗
  19. Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. Co-author DOI 10.1016/j.scr.2016.08.007↗
  20. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Co-author DOI 10.1136/gutjnl-2014-308935↗
  21. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Co-author DOI 10.1053/j.gastro.2014.08.002↗
  22. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. Co-author DOI 10.1371/journal.pone.0066371↗
  23. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. First author DOI 10.1016/j.stem.2011.10.001↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bruno Sáinz · 18 shared papers, 2013–2026 · strength 1.83
  2. Thomas Theodor Werner Seufferlein · 10 shared papers, 2016–2026 · strength 1.05
  3. Sonia Alcalá · 10 shared papers, 2011–2026 · strength 1.04
  4. Alexander Kleger · 7 shared papers, 2016–2026 · strength 0.80
  5. Karolin Walter · 8 shared papers, 2016–2026 · strength 0.79
  6. Frank Arnold · 6 shared papers, 2020–2026 · strength 0.76
  7. Kanishka Tiwary · 5 shared papers, 2019–2026 · strength 0.57
  8. Eva Rodríguez-Aznar · 5 shared papers, 2019–2021 · strength 0.48
  9. Christopher Heeschen · 7 shared papers, 2011–2023 · strength 0.46
  10. Elisabeth Heßmann · 3 shared papers, 2021–2026 · strength 0.46
  11. Patricia Sancho Andrés · 6 shared papers, 2014–2023 · strength 0.45
  12. Paola Martinelli · 5 shared papers, 2014–2023 · strength 0.45
  13. Johann Gout · 4 shared papers, 2019–2026 · strength 0.43
  14. Lukas Perkhofer · 4 shared papers, 2016–2026 · strength 0.39
  15. Sandra Valle · 4 shared papers, 2019–2023 · strength 0.37
  16. Pierre‐Olivier Frappart · 4 shared papers, 2020–2021 · strength 0.35
  17. Mert Erkan · 4 shared papers, 2015–2023 · strength 0.34
  18. Juan Carlos López-Gil · 2 shared papers, 2023–2024 · strength 0.30
  19. Alfredo Carrato Mena · 3 shared papers, 2019–2023 · strength 0.29
  20. Julie Earl · 3 shared papers, 2019–2023 · strength 0.29
  21. Marta Alonso‐Nocelo · 3 shared papers, 2019–2023 · strength 0.28
  22. Élodie Roger · 2 shared papers, 2021–2026 · strength 0.27
  23. Roland Rad · 2 shared papers, 2021–2026 · strength 0.27
  24. Stephan A. Hahn · 3 shared papers, 2013–2023 · strength 0.26
  25. Anton Lahusen · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.